TIM-3
42 programs · 42 companies
Programs
42
Companies
42
Active Trials
23
Targeting TIM-3
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| REG-6699 | Regeneron | Phase 2/3 | Heart FailureCrohn's | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | RettMG | |
| Liratinib | Krystal Biotech | NDA/BLA | Meso | |
| Doxazasiran | Axsome | Phase 1 | BCCPTSD | |
| Rimanesiran | Merus | Phase 1 | RSV | |
| Niratinib | Alumis | NDA/BLA | Urothelial Ca | |
| TER-8735 | Terns | Phase 1/2 | NarcolepsyPancreatic Ca | |
| 451-4848 | Chugai | Preclinical | NBAML | |
| Doxafotisoran | Otsuka | NDA/BLA | PompeBCC | |
| CAM-IIT-257 | CAMS | Phase 2/3 | ACC | |
| Geliinavolisib | Isomorphic Labs | NDA/BLA | CF | |
| AER-1540 | Aera Ther | Phase 2/3 | Melanoma | |
| ADI-7213 | Adicet (Regeneron) | Phase 2/3 | Huntington'sPNH | |
| ACO-697 | ACLARION | Phase 1/2 | Hemophilia AWilms | |
| CON-544 | ContraFect (Phibro) | NDA/BLA | SLEThymoma | |
| Sotoinavolisib | Eledon Pharma | Phase 1 | Ovarian CaPTSD | |
| BLP-8787 | Bellerophon | Approved | Huntington'sAML | |
| Pemibrutinib | Vaxxinity | Approved | Pancreatic CaLGS | |
| 195-4808 | Everest Medicines | Preclinical | HCCALS | |
| 993-1656 | Kintor Pharma | Preclinical | RA | |
| Capicagene | GW Pharma (Jazz) | Approved | PsAAsthma | |
| Zanutuximab | Pieris Pharma | Phase 1 | Cervical Ca | |
| DUK-IIT-640 | Duke Cancer | NDA/BLA | MCL | |
| MIM-9595 | Mimetogen | Preclinical | RSV | |
| GEN-IIT-770 | Genethon | Phase 1 | Melanoma | |
| ONC-9294 | Oncolytics Bio | Approved | TTR AmyloidosisT2D | |
| Zanuratamab | Nichi-Iko | Phase 1 | TTR AmyloidosisFSGS | |
| 456-7078 | Sosei Heptares | Phase 1/2 | AngelmanEpilepsy | |
| HIK-6819 | Hikma Pharma | Preclinical | Wet AMD | |
| Geliglumide | Pacific Biosciences | Phase 2/3 | PNHMCL | |
| Elracapivasertib | Servier | Phase 1/2 | OCD | |
| Sotomavacamten | MiRXES | NDA/BLA | NSCLCPNH | |
| Sovasacituzumab | BioVersys | Phase 2 | Endometrial CaHCC | |
| DIV-7153 | Divi's Laboratories | Preclinical | PompeIPF | |
| ZYD-5095 | Zydus Lifesciences | Phase 2 | PTSD | |
| FUD-IIT-103 | Fudan Cancer Hosp | Preclinical | RA | |
| RUI-IIT-540 | Ruijin Hospital | Approved | NSCLC | |
| EUP-4341 | Eupraxia Pharma | Preclinical | Hemophilia A | |
| VIR-5831 | Virbac | Phase 1/2 | Ovarian Ca | |
| VEE-3535 | Veeva Systems | NDA/BLA | Cervical CaMCC | |
| Gozefutibatinib | Definiens | Preclinical | EoE | |
| 453-180 | Santen Pharma | Phase 3 | AS |